Skip to main content
SpringerLink
Log in

Using Contraceptives for Gynecologic Conditions

  • Chapter
  • First Online:
Contraception for the Medically Challenging Patient

  • 1021 Accesses

Abstract

Contraceptive medications commonly serve as therapy for gynecologic conditions other than pregnancy prevention. For the treating clinician, it is important to understand the data supporting the use of contraception for such indications. In some cases, research investigations have demonstrated clear benefits for using certain contraceptives for various gynecologic conditions. In others, only limited published research exists to guide treatment options or the use of a contraceptive for a particular disease remains unstudied. What follows is a contemporary review of the available evidence concerning several common disorders seen by women’s health care providers. In doing so, it is our goal that this text may serve as a reference for clinicians faced with gynecologic treatment dilemmas. As is appropriate in all medical fields, the use of contraceptives for gynecologic conditions should be as evidence based as possible.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Munro MG, Critchley HO, Broder MS, Fraser IS, Disorders FWGoM. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113(1):3–13.

    Article  PubMed  Google Scholar 

  2. U. S. Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recomm Rep. 2010; 59(RR-4):1–86.

    Google Scholar 

  3. Committee on Practice B-G. Practice bulletin no. 128: diagnosis of abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol. 2012; 120(1):197–206.

    Article  Google Scholar 

  4. Kelekci S, Kelekci KH, Yilmaz B. Effects of levonorgestrel-releasing intrauterine system and T380A intrauterine copper device on dysmenorrhea and days of bleeding in women with and without adenomyosis. Contraception. 2012;86(5):458–63.

    Article  CAS  PubMed  Google Scholar 

  5. Sheng J, Zhang WY, Zhang JP, Lu D. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception. 2009;79(3):189–93.

    Article  CAS  PubMed  Google Scholar 

  6. Bragheto AM, Caserta N, Bahamondes L, Petta CA. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception. 2007;76(3):195–9.

    Article  CAS  PubMed  Google Scholar 

  7. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2006;2, CD003855.

    PubMed  Google Scholar 

  8. Maia Jr H, Casoy J, Pimentel K, Correia T, Athayde C, Cruz T, et al. Effect of oral contraceptives on vascular endothelial growth factor, Cox-2 and aromatase expression in the endometrium of uteri affected by myomas and associated pathologies. Contraception. 2008;78(6):479–85.

    Article  CAS  PubMed  Google Scholar 

  9. Olufowobi O, Sharif K, Papaionnou S, Neelakantan D, Mohammed H, Afnan M. Are the anticipated benefits of myomectomy achieved in women of reproductive age? A 5-year review of the results at a UK tertiary hospital. J Obstet Gynaecol. 2004;24(4): 434–40.

    Article  CAS  PubMed  Google Scholar 

  10. Stewart EA, Nowak RA. Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Hum Reprod Update. 1996;2(4):295–306.

    Article  CAS  PubMed  Google Scholar 

  11. Wegienka G, Baird DD, Hertz-Picciotto I, Harlow SD, Steege JF, Hill MC, et al. Self-reported heavy bleeding associated with uterine leiomyomata. Obstet Gynecol. 2003;101(3):431–7.

    Article  PubMed  Google Scholar 

  12. Zapata LB, Whiteman MK, Tepper NK, Jamieson DJ, Marchbanks PA, Curtis KM. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception. 2010;82(1):41–55.

    Article  PubMed  Google Scholar 

  13. Sayed GH, Zakherah MS, El-Nashar SA, Shaaban MM. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int J Gynaecol Obstet. 2011;112(2):126–30.

    Article  CAS  PubMed  Google Scholar 

  14. Socolov D, Blidaru I, Tamba B, Miron N, Boiculese L, Socolov R. Levonorgestrel releasing-intrauterine system for the treatment of menorrhagia and/or frequent irregular uterine bleeding associated with uterine leiomyoma. Eur J Contracept Reprod Health Care. 2011;16(6):480–7.

    Article  CAS  PubMed  Google Scholar 

  15. Xie ZW, Zhang YN, Wan S, Xu WZ, Chen J. Levonorgestrel-releasing intrauterine device is an efficacious contraceptive for women with leiomyoma. J Int Med Res. 2012;40(5):1966–72.

    Article  CAS  PubMed  Google Scholar 

  16. Kriplani A, Awasthi D, Kulshrestha V, Agarwal N. Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma. Int J Gynaecol Obstet. 2012;116(1):35–8.

    Article  CAS  PubMed  Google Scholar 

  17. Sangkomkamhang US, Lumbiganon P, Laopaiboon M, Mol BW. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids. Cochrane Database Syst Rev. 2013;2, CD008994.

    PubMed  Google Scholar 

  18. Orsini G, Laricchia L, Fanelli M. Low-dose combination oral contraceptives use in women with uterine leiomyomas. Minerva Ginecol. 2002;54(3):253–61.

    CAS  PubMed  Google Scholar 

  19. Venkatachalam S, Bagratee JS, Moodley J. Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study. J Obstet Gynaecol. 2004;24(7):798–800.

    Article  CAS  PubMed  Google Scholar 

  20. American College of O, Gynecologists. ACOG committee opinion no. 557: management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet Gynecol. 2013;121(4):891–6.

    Article  Google Scholar 

  21. American College of O, Gynecologists Committee on Adolescent Health C, American College of O, Gynecologists Committee Gynecologic P. ACOG Committee Opinion No. 451: Von Willebrand disease in women. Obstet Gynecol. 2009;114(6):1439–43.

    Article  Google Scholar 

  22. Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG. 2004;111(12): 1425–8.

    Article  CAS  PubMed  Google Scholar 

  23. Foster PA. The reproductive health of women with von Willebrand Disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost. 1995;74(2):784–90.

    CAS  PubMed  Google Scholar 

  24. Pitangui AC, Gomes MR, Lima AS, Schwingel PA, Albuquerque AP, de Araujo RC. Menstruation disturbances: prevalence, characteristics, and effects on the activities of daily living among adolescent girls from Brazil. J Pediatr Adoles Gynecol. 2013;26(3): 148–52.

    Article  Google Scholar 

  25. Chia CF, Lai JH, Cheung PK, Kwong LT, Lau FP, Leung KH, et al. Dysmenorrhoea among Hong Kong university students: prevalence, impact, and management. Hong Kong Med J. 2013;19(3):222–8.

    CAS  PubMed  Google Scholar 

  26. Grandi G, Ferrari S, Xholli A, Cannoletta M, Palma F, Romani C, et al. Prevalence of menstrual pain in young women: what is dysmenorrhea? J Pain Res. 2012;5:169–74.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Dawood MY. Ibuprofen and dysmenorrhea. Am J Med. 1984;77(1A):87–94.

    Article  CAS  PubMed  Google Scholar 

  28. Ronnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand. 1999;78(8):716–21.

    Article  CAS  PubMed  Google Scholar 

  29. Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)—a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol. 2006;125(1): 9–28.

    Article  CAS  PubMed  Google Scholar 

  30. Lalos O, Joelsson I. Effect of salbutamol on the non-pregnant human uterus in vivo. A hysterometric study in dysmenorrheic women. Acta Obstet Gynecol Scand. 1981;60(4):349–52.

    Article  CAS  PubMed  Google Scholar 

  31. Milsom I, Lete I, Bjertnaes A, Rokstad K, Lindh I, Gruber CJ, et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. Hum Reprod. 2006;21(9):2304–11.

    Article  CAS  PubMed  Google Scholar 

  32. Robinson JC, Plichta S, Weisman CS, Nathanson CA, Ensminger M. Dysmenorrhea and use of oral contraceptives in adolescent women attending a family planning clinic. Am J Obstet Gynecol. 1992;166(2):578–83.

    Article  CAS  PubMed  Google Scholar 

  33. Davis AR, Westhoff C, O'Connell K, Gallagher N. Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial. Obstet Gynecol. 2005;106(1):97–104.

    Article  CAS  PubMed  Google Scholar 

  34. Winkler UH, Ferguson H, Mulders JA. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. Contraception. 2004;69(6):469–76.

    Article  CAS  PubMed  Google Scholar 

  35. Dmitrovic R, Kunselman AR, Legro RS. Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol. 2012;119(6):1143–50.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. French L. Dysmenorrhea. Am Fam Physician. 2005;71(2):285–91.

    PubMed  Google Scholar 

  37. Funk S, Miller MM, Mishell Jr DR, Archer DF, Poindexter A, Schmidt J, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception. 2005;71(5): 319–26.

    Article  CAS  PubMed  Google Scholar 

  38. Croxatto HB. Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care. 2000;5 Suppl 2:21–8.

    CAS  PubMed  Google Scholar 

  39. Practice bulletin no. 114: management of endometriosis. Obstet Gynecol. 2010;116(1):223–36.

    Google Scholar 

  40. Lockhat FB, Emembolu JO, Konje JC. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod. 2005;20(3):789–93.

    Article  CAS  PubMed  Google Scholar 

  41. Petta CA, Ferriani RA, Abrao MS, Hassan D, Rosa ESJC, Podgaec S, et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod. 2005;20(7):1993–8.

    Article  CAS  PubMed  Google Scholar 

  42. Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R, Crosignani PG. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril. 2003;80(3):560–3.

    Article  PubMed  Google Scholar 

  43. Vessey MP, Villard-Mackintosh L, Painter R. Epidemiology of endometriosis in women attending family planning clinics. BMJ. 1993;306(6871): 182–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Crosignani PG, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod. 2006;21(1):248–56.

    Article  CAS  PubMed  Google Scholar 

  45. Schlaff WD, Carson SA, Luciano A, Ross D, Bergqvist A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril. 2006;85(2):314–25.

    Article  CAS  PubMed  Google Scholar 

  46. Harada T, Momoeda M, Taketani Y, Hoshiai H, Terakawa N. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril. 2008;90(5):1583–8.

    Article  PubMed  Google Scholar 

  47. Seracchioli R, Mabrouk M, Frasca C, Manuzzi L, Montanari G, Keramyda A, et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertil Steril. 2010;93(1):52–6.

    Article  PubMed  Google Scholar 

  48. Seracchioli R, Mabrouk M, Manuzzi L, Vicenzi C, Frasca C, Elmakky A, et al. Post-operative use of oral contraceptive pills for prevention of anatomical relapse or symptom-recurrence after conservative surgery for endometriosis. Hum Reprod. 2009; 24(11):2729–35.

    Article  CAS  PubMed  Google Scholar 

  49. Abou-Setta AM, Al-Inany HG, Farquhar CM. Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery. Cochrane Database Syst Rev. 2006;4, CD005072.

    PubMed  Google Scholar 

  50. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100–7.

    Article  PubMed  Google Scholar 

  51. Practice Bulletin ACOG. Alternatives to hysterectomy in the management of leiomyomas. Obstet Gynecol. 2008;112(2 Pt 1):387–400.

    Google Scholar 

  52. Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JT. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J (Clin Res Ed). 1986;293(6543):359–62.

    Article  CAS  Google Scholar 

  53. Marshall LM, Spiegelman D, Goldman MB, Manson JE, Colditz GA, Barbieri RL, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril. 1998;70(3):432–9.

    Article  CAS  PubMed  Google Scholar 

  54. Wise LA, Palmer JR, Harlow BL, Spiegelman D, Stewart EA, Adams-Campbell LL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol. 2004;159(2):113–23.

    Article  PubMed Central  PubMed  Google Scholar 

  55. Magalhaes J, Aldrighi JM, de Lima GR. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception. 2007;75(3):193–8.

    Article  CAS  PubMed  Google Scholar 

  56. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data. Vital Health Stat. 2005;13(158):1–199.

    Google Scholar 

  57. Vessey M, Metcalfe A, Wells C, McPherson K, Westhoff C, Yeates D. Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. Br Med J (Clin Res Ed). 1987;294(6586):1518–20.

    Article  CAS  Google Scholar 

  58. Ory H. Boston Collaborative Drug Surveillance Program. Functional ovarian cysts and oral contraceptives. Negative association confirmed surgically. A cooperative study. JAMA. 1974;228:68–79.

    Article  Google Scholar 

  59. Lanes SF, Birmann B, Walker AM, Singer S. Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol. 1992;166(3):956–61.

    Article  CAS  PubMed  Google Scholar 

  60. Holt VL, Daling JR, McKnight B, Moore D, Stergachis A, Weiss NS. Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives. Obstet Gynecol. 1992;79(4):529–33.

    CAS  PubMed  Google Scholar 

  61. Grimes DA, Godwin AJ, Rubin A, Smith JA, Lacarra M. Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial. Obstet Gynecol. 1994;83(1):29–34.

    CAS  PubMed  Google Scholar 

  62. Christensen JT, Boldsen JL, Westergaard JG. Functional ovarian cysts in premenopausal and gynecologically healthy women. Contraception. 2002;66(3):153–7.

    Article  PubMed  Google Scholar 

  63. Grimes DA, Jones LB, Lopez LM, Schulz KF. Oral contraceptives for functional ovarian cysts. Cochrane Database Syst Rev. 2006;9, CD006134.

    Google Scholar 

  64. Tayob Y, Adams J, Jacobs HS, Guillebaud J. Ultrasound demonstration of increased frequency of functional ovarian cysts in women using progestogen-only oral contraception. Br J Obstet Gynaecol. 1985;92(10):1003–9.

    Article  CAS  PubMed  Google Scholar 

  65. Hidalgo MM, Lisondo C, Juliato CT, Espejo-Arce X, Monteiro I, Bahamondes L. Ovarian cysts in users of Implanon and Jadelle subdermal contraceptive implants. Contraception. 2006;73(5):532–6.

    Article  CAS  PubMed  Google Scholar 

  66. Turan C, Zorlu CG, Ugur M, Ozcan T, Kaleli B, Gokmen O. Expectant management of functional ovarian cysts: an alternative to hormonal therapy. Int J Gynaecol Obstet. 1994;47(3):257–60.

    Article  CAS  PubMed  Google Scholar 

  67. Johnson SR. Premenstrual syndrome, premenstrual dysphoric disorder, and beyond: a clinical primer for practitioners. Obstet Gynecol. 2004;104(4):845–59.

    Article  PubMed  Google Scholar 

  68. Sternfeld B, Swindle R, Chawla A, Long S, Kennedy S. Severity of premenstrual symptoms in a health maintenance organization population. Obstet Gynecol. 2002;99(6):1014–24.

    Article  PubMed  Google Scholar 

  69. Graham CA, Sherwin BB. The relationship between mood and sexuality in women using an oral contraceptive as a treatment for premenstrual symptoms. Psychoneuroendocrinology. 1993;18(4):273–81.

    Article  CAS  PubMed  Google Scholar 

  70. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106(3):492–501.

    Article  CAS  PubMed  Google Scholar 

  71. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. Concurrent use of oral contraceptives with antidepressants for premenstrual syndromes. J Clin Psychopharmacol. 2001;21(5):540–2.

    Article  CAS  PubMed  Google Scholar 

  72. Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care. 2000;5(2):124–34.

    Article  CAS  PubMed  Google Scholar 

  73. Edelman AB, Gallo MF, Jensen JT, Nichols MD, Schulz KF, Grimes DA. Continuous or extended cycle vs cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2005;3, CD004695.

    PubMed  Google Scholar 

  74. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2012;2, CD006586.

    PubMed  Google Scholar 

  75. Centers for Disease Control [Internet]. Atlanta: Centers for Disease Control: 2012 [cited 2013 Feb 11]. Available at www.cdc.gov/std/chlamydia.htm. 2012.

  76. Centers for Disease Control [Internet]. Atlanta: Centers for Disease Control; 2014 [cited 2014 Jan 8]. Available at http://www.cdc/std/stats12/Surv2012.pdf. 2014.

  77. Centers for Disease Control [Internet]. Atlanta: Centers for Disease Control: 2012 [cited 2013 May 22] Available at http://www.cdc.gov/nchhsstp/newsroom/docs/2012/HIV-Infections-2007-2010.pdf. 2012.

  78. Cates Jr W. Review of non-hormonal contraception (condoms, intrauterine devices, nonoxynol-9 and combos) on HIV acquisition. J Acquir Immune Defic Syndr. 2005;38 Suppl 1:S8–10.

    Article  PubMed  Google Scholar 

  79. Farr G, Gabelnick H, Sturgen K, Dorflinger L. Contraceptive efficacy and acceptability of the female condom. Am J Public Health. 1994;84(12):1960–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  80. Trussel J. Contraceptive Efficacy. In: Hatcher RA, editor. Contraceptive technology. 20th ed. New York: Ardent Media; 2011.

    Google Scholar 

  81. Henry-Suchet J. Hormonal contraception and pelvic inflammatory disease. Eur J Contracept Reprod Health Care. 1997;2(4):263–7.

    Article  CAS  PubMed  Google Scholar 

  82. Baeten JM, Nyange PM, Richardson BA, Lavreys L, Chohan B, Martin Jr HL, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol. 2001;185(2):380–5.

    Article  CAS  PubMed  Google Scholar 

  83. Washington AE, Gove S, Schachter J, Sweet RL. Oral contraceptives, Chlamydia trachomatis infection, and pelvic inflammatory disease. A word of caution about protection. JAMA. 1985;253(15): 2246–50.

    Article  CAS  PubMed  Google Scholar 

  84. Burkman RT. Oral contraceptives: current status. Clin Obstet Gynecol. 2001;44(1):62–72.

    Article  CAS  PubMed  Google Scholar 

  85. Morrison CS, Skoler-Karpoff S, Kwok C, Chen PL, van de Wijgert J, Gehret-Plagianos M, et al. Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS. 2012;26(4):497–504.

    Article  CAS  PubMed  Google Scholar 

  86. Torok MR, Miller WC, Hobbs MM, Macdonald PD, Leone PA, Schwebke JR, et al. The association between oral contraceptives, depot-medroxyprogesterone acetate, and trichomoniasis. Sex Transm Dis. 2009;36(6): 336–40.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  87. Moreno V, Bosch FX, Munoz N, Meijer CJ, Shah KV, Walboomers JM, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 2002;359(9312):1085–92.

    Article  CAS  PubMed  Google Scholar 

  88. Marks M, Gravitt PE, Gupta SB, Liaw KL, Tadesse A, Kim E, et al. Combined oral contraceptive use increases HPV persistence but not new HPV detection in a cohort of women from Thailand. J Infect Dis. 2011;204(10):1505–13.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  89. Nielsen A, Kjaer SK, Munk C, Osler M, Iftner T. Persistence of high-risk human papillomavirus infection in a population-based cohort of Danish women. J Med Virol. 2010;82(4):616–23.

    Article  PubMed  Google Scholar 

  90. Harris TG, Miller L, Kulasingam SL, Feng Q, Kiviat NB, Schwartz SM, et al. Depot-medroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among women with oncogenic human papillomavirus infection. Am J Obstet Gynecol. 2009;200(5):489.e1–8.

    Google Scholar 

  91. Syrjanen K, Shabalova I, Petrovichev N, Kozachenko V, Zakharova T, Pajanidi J, et al. Oral contraceptives are not an independent risk factor for cervical intraepithelial neoplasia or high-risk human papillomavirus infections. Anticancer Res. 2006;26(6C): 4729–40.

    PubMed  Google Scholar 

  92. Longatto-Filho A, Hammes LS, Sarian LO, Roteli-Martins C, Derchain SF, Erzen M, et al. Hormonal contraceptives and the length of their use are not independent risk factors for high-risk HPV infections or high-grade CIN. Gynecol Obstet Invest. 2011;71(2):93–103.

    Article  CAS  PubMed  Google Scholar 

  93. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370(9599):1609–21.

    Article  PubMed  Google Scholar 

  94. Romer A, Shew ML, Ofner S, Gilliam ML, Martins SL, Fortenberry JD. Depot medroxyprogesterone acetate use is not associated with risk of incident sexually transmitted infections among adolescent women. J Adolesc Health. 2013;52(1):83–8.

    Article  PubMed Central  PubMed  Google Scholar 

  95. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis. 2012;12(1):19–26.

    Article  PubMed Central  PubMed  Google Scholar 

  96. Morrison CS, Chen PL, Kwok C, Richardson BA, Chipato T, Mugerwa R, et al. Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. Aids. 2010;24(11): 1778–81.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  97. Kleinschmidt I, Rees H, Delany S, Smith D, Dinat N, Nkala B, et al. Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort. Contraception. 2007;75(6):461–7.

    Article  CAS  PubMed  Google Scholar 

  98. Myer L, Denny L, Wright TC, Kuhn L. Prospective study of hormonal contraception and women’s risk of HIV infection in South Africa. Int J Epidemiol. 2007;36(1):166–74.

    Article  PubMed  Google Scholar 

  99. Jain AK. Hormonal contraception and HIV acquisition risk: implications for individual users and public policies. Contraception. 2012;86(6):645–52.

    Article  PubMed  Google Scholar 

  100. Rodriguez MI, Reeves MF, Caughey AB. Evaluating the competing risks of HIV acquisition and maternal mortality in Africa: a decision analysis. BJOG. 2012;119(9):1067–73.

    Article  CAS  PubMed  Google Scholar 

  101. Centers for Disease Control and Prevention. Update to CDC’s U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV. MMWR. 2012;61(24):449–52.

    Google Scholar 

  102. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet. 1992;339(8796):785–8.

    Article  CAS  PubMed  Google Scholar 

  103. Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet. 2000;356(9234):1013–9.

    Article  CAS  PubMed  Google Scholar 

  104. Stanback J, Shelton JD. Pelvic inflammatory disease attributable to the IUD: modeling risk in West Africa. Contraception. 2008;77(4):227–9.

    Article  PubMed  Google Scholar 

  105. Sufrin CB, Postlethwaite D, Armstrong MA, Merchant M, Wendt JM, Steinauer JE. Neisseria gonorrhea and Chlamydia trachomatis screening at intrauterine device insertion and pelvic inflammatory disease. Obstet Gynecol. 2012;120(6):1314–21.

    PubMed  Google Scholar 

  106. Division of Reproductive Health NCfCDP, Health Promotion CfDC, Prevention. U.S. Selected Practice Recommendations for Contraceptive Use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use, 2nd edition. MMWR Recomm Rep. 2013;62(RR-05):1–60.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Baystate Medical Center, Tufts University School of Medicine, Springfield, MA, USA

    David R. Kattan M.D., M.P.H. & Ronald T. Burkman M.D.

Authors
  1. David R. Kattan M.D., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronald T. Burkman M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ronald T. Burkman M.D. .

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA

    Rebecca H. Allen

  2. Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia, USA

    Carrie A. Cwiak

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kattan, D.R., Burkman, R.T. (2014). Using Contraceptives for Gynecologic Conditions. In: Allen, R., Cwiak, C. (eds) Contraception for the Medically Challenging Patient. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1233-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1233-9_13

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1232-2

  • Online ISBN: 978-1-4939-1233-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation